Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO an... von Wu, Y.-L., Planchard, D., Lu, S., Sun, H., Yamamoto, N., Kim, D.-W., Tan, D.S.W., Yang, J.C.-H., Azrif, M., Mitsudomi, T., Park, K., Soo, R.A., Chang, J.W.C., Alip, A., Peters, S., Douillard, J.-Y.

Volltext

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by... von Park, K., Vansteenkiste, J., Lee, K.H., Pentheroudakis, G., Zhou, C., Prabhash, K., Seto, T., Voon, P.J., Tan, D.S.W., Yang, J.C.H., Wang, J., Babu, K. Govind, Nakayama, Y., Alip, A., Chua, K.L.M., Cheng, J.C.-H., Senan, S., Ahn, Y.C., Kim, T.-Y., Ahn, H.K., Peters, S., Yoshino, T., Douillard, J.-Y.

Volltext

Effectiveness of Decision Aid in Men with Localized Prostate Cancer: a Multicenter Randomized Controlled Trial at Tertiary Referral Hospitals in an Asia Pacific Country von Jalil, N. B., Lee, P. Y., Nor Afiah, M. Z., Abdullah, K. L., Azizi, F. N. S. Mohd, Rassip, N. N. S. Abdul, Ong, T. A., Ng, C. J., Lee, Y. K., Cheong, A. T., Razack, A. H., Saad, M., Alip, A., Malek, R., Sundram, M., Omar, S., Sathiyananthan, J. R., Kumar, P.

Volltext

1023 Prostate cancer in multi-ethnic Asian men von Lim, J, Bhoo-pathy, N, Sothilingam, S, Alip, A, Saad, M, Ong, T, Razack, A

Volltext

100 Continuous hyperfractionated accelerated radiotherapy (CHART) for patients with inoperable non-small cell lung Cancer (NSCLC): 10 year experience of the Exeter Oncology Centre von Alip, A, Toy, E.W

Volltext

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions von Zhou, Caicun, Tang, Ke-Jing, Cho, Byoung Chul, Liu, Baogang, Paz-Ares, Luis, Cheng, Susanna, Kitazono, Satoru, Thiagarajan, Muthukkumaran, Goldman, Jonathan W, Sabari, Joshua K, Sanborn, Rachel E, Mansfield, Aaron S, Hung, Jen-Yu, Boyer, Michael, Popat, Sanjay, Mourão Dias, Josiane, Felip, Enriqueta, Majem, Margarita, Gumus, Mahmut, Kim, Sang-We, Ono, Akira, Xie, John, Bhattacharya, Archan, Agrawal, Trishala, Shreeve, S Martin, Knoblauch, Roland E, Park, Keunchil, Girard, Nicolas

Volltext

354P Knowledge, perception, and attitude of oncology-related healthcare providers on complementary and alternative medicine (CAM) von Tan, C.K., Alip, A., Jye, V. Pei, Ismail, F.

Volltext

147 Sequential chemotherapy and continuous hyperfractionated accelerated radiotherapy (CHART) for non-small cell lung cancer (NSCLC): experience from nine UK centres von Bradshaw, A.G, Lester, J.E, Das, T, Esler, C, Branagan, J, Roy, A.E.F, Toy, E.W, Alip, A, Lester, J.F, Williams, R, Kinsman, J, Comins, C, Atherton, P, Knox, C, Morgan, S, Walker, G.A, Hatton, M.Q

Volltext

289P The treatment outcome of metastatic prostate cancer patients treated with androgen deprivation therapy in University Malaya Medical Centre von Yehgambaram, P., Alip, A., Saad, M.

Volltext

289P The treatment outcome of metastatic prostate cancer patients treated with androgen deprivation therapy in University Malaya Medical Centre von Yehgambaram, P., Alip, A., Saad, M.

Volltext

LBA6 A phase II, single arm, open label, Simon two-stage study of pembrolizumab in metastatic HER2-negative breast cancer patients: Evaluation of impact of germline variants in APO... von Ho, G.F., Lee, S.C., Pan, J.W., Bustam, A.Z., Alip, A., Bt Abdul Satar, N.F., Saad, M., Abdul Malik, R., Lim, S.E., Ow, S., Ngoi, N.Y.L., Law, K.B., Toh, Y.Y., Selvam, B., Lim, J., Teo, S-H.

Volltext

LBA10 Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup anal... von Lu, S., Cho, B.C., Lee, J-S., Lee, S-H., Danchaivijitr, P., Liu, B., Alip, A., Xiong, H., How, S.H., Chang, G-C., Yang, J.C-H., Yoshioka, H., Xia, K., Martinez, M., Bauml, J.M., Sethi, S., Hayashi, H.

Volltext

Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma von Chai, C.S., Liam, C.K., Po Lin, O., Pang, Y.K., Ho, G.F., Alip, A., Wong, C.K., Poh, M.E., Tan, J.L.

Volltext

Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib... von Chai, C.S., Po Lin, O., Liam, C.K., Pang, Y.K., Ho, G.F., Alip, A., Wong, C.K., Poh, M.E., Tan, J.L.

Volltext

EP1.14-17 Acquired T790M Mutation in Patients Failing Treatment with First or Second-Generation EGFR-Tyrosine Kinase Inhibitors von Liam, C.K., Chai, C.S., Poh, M.E., Ong, D.B.L., Cheah, P.L., Pang, Y.K., Ho, G.F., Alip, A.

Volltext

LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA,... von Cho, B.C., Felip, E., Spira, A.I., Girard, N., Lee, J-S., Lee, S-H., Ostapenko, Y.V., Danchaivijitr, P., Liu, B., Alip, A., Korbenfeld, E.P., Dias, J., Sun, T., Martinez, M., Bauml, J.M., Shreeve, M., Sethi, S., Knoblauch, R.E., Hayashi, H., Lu, S.

Volltext

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOS... von Felip, E., Cho, B.C., Gutiérrez, V., Alip, A., Besse, B., Lu, S., Spira, A.I., Girard, N., Califano, R., Gadgeel, S.M., Yang, J.C.-H., Yamamoto, S., Azuma, K., Kim, Y.J., Lee, K.-H., Danchaivijitr, P., Ferreira, C.G., Cheng, Y., Sendur, M.A.N., Chang, G.-C., Wang, C.-C., Prabhash, K., Shinno, Y., Stroyakovskiy, D., Paz-Ares, L., Rodriguez-Cid, J.R., Martin, C., Campelo, M.R.G., Hayashi, H., Nguyen, D., Tomasini, P., Gottfried, M., Dooms, C., Passaro, A., Schuler, M., Gelatti, A.C.Z., Owen, S., Perdrizet, K., Ou, S.-H.I., Curtin, J.C., Zhang, J., Gormley, M., Sun, T., Panchal, A., Ennis, M., Fennema, E., Daksh, M., Sethi, S., Bauml, J.M., Lee, S.-H.

Volltext

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOS... von Felip, E, Cho, B.C, Gutierrez, V, Alip, A, Besse, B, Lu, S, Spira, A.I, Girard, N, Califano, R, Gadgeel, S.M, Yang, J.C.-H, Yamamoto, S, Azuma, K, Kim, Y.J, Lee, K.-H, Danchaivijitr, P, Ferreira, C.G, Cheng, Y, Sendur, M.A.N, Chang, G.-C, Wang, C.-C, Prabhash, K, Shinno, Y, Stroyakovskiy, D, Paz-Ares, L, Rodriguez-Cid, J.R, Martin, C, Campelo, M.R.G, Hayashi, H, Nguyen, D, Tomasini, P, Gottfried, M, Dooms, C, Passaro, A, Schuler, M, Gelatti, A.C.Z, Owen, S, Perdrizet, K, Ou, S.-H.I, Curtin, J.C, Zhang, J, Gormley, M, Sun, T, Panchal, A, Ennis, M, Fennema, E, Bauml, J.M, Daksh, M, Sethi, S, Lee, S.-H

Volltext

Quantification of plasma epstein-barr virus dna in patients with nasopharyngeal carcinoma: Preliminary results of a prospective study von Özvar, E, Gultekin, M, Alip, A, Hascelik, G, Hosal, S, Atahan, I

Volltext

OA02.05 Lazertinib vs Osimertinib in 1L EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis from MARIPOSA von Lee, S.-H., Cho, B.C., Hayashi, H., Felip, E., Spira, A.I., Girard, N., Kim, Y.J., Ostapenko, Y., Danchaivijitr, P., Liu, B., Alip, A., Korbenfeld, E., Mourão Dias, J., Lee, K.H., Xiong, H., How, S.H., Cheng, Y., Chang, G.-C., Yang, J.C.-H., Besse, B., Thomas, M., Curtin, J.C., Zhang, J., Xie, J., Sun, T., Martinez, M., Sethi, S., Knoblauch, R.E., Fennema, E., Daksh, M., Ennis, M., Bauml, J.M., Lu, S.

Volltext